Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 16, 2018. The document serves as a transaction notification regarding dealings in the company's ordinary shares by Persons Discharging Managerial Responsibilities (PDMRs).
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It is strictly a disclosure of specific share transactions.
| Transaction Date | Instrument | Price per Share | Volume | Transaction Type |
|---|---|---|---|---|
| July 13, 2018 | Ordinary Shares (25p) | £15.865 | 23 | Acquisition (Dividend Re-investment) |
| July 13, 2018 | Ordinary Shares (25p) | £15.865 | 19 | Acquisition (Dividend Re-investment) |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details routine acquisitions of shares by two executives following the re-investment of dividends paid on July 12, 2018.
Management Commentary and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. The transactions were executed on the London Stock Exchange (XLON) within Individual Savings Accounts (ISAs).
Key Facts for Investor Verification
- Transaction Nature: Both transactions were automatic acquisitions resulting from dividend re-investment plans, not open market purchases.
- Executives Involved: Mr. D S Redfern (Chief Strategy Officer) and Mrs. V A Whyte (Company Secretary).
- Share Price: The acquisition price was £15.865 per share.
- Volume: The total volume disclosed in this specific filing is 42 shares (23 + 19).
- Financial Data: This filing does not contain quarterly or annual financial results; investors should refer to Form 20-F for comprehensive financial data.